Yonsei Med J.  2009 Jun;50(3):331-334. 10.3349/ymj.2009.50.3.331.

Genetic and Epigenetic Marker-Based DNA Test of Stool Is a Promising Approach for Colorectal Cancer Screening

• An SW
• Kim NK
• Chung HC

• KMID: 1758558
• DOI: http://doi.org/10.3349/ymj.2009.50.3.331

Abstract

Colorectal cancer (CRC) is one of the most common malignancies and leading cause of cancer-related deaths in the world. However, it may be treated effectively by surgical removal of the cancerous tissue if detected at early stages. Conventional tools for screening CRC are either invasive or inaccurate. Therefore, there is an urgent need to develop a reliable screening tools for CRC to significantly reduce its morbidity. In this regard, a novel DNA markers-based detection in stool is emerging as a promising approach.

Keyword

Colorectal cancer screening; stool DNA; genetic and epigenetic alterations

MeSH Terms

Colorectal Neoplasms/*diagnosis/*genetics
Epigenesis, Genetic/*genetics
*Feces
Genetic Markers/*genetics
Tumor Markers, Biological/genetics

Reference

1. Dong SM, Traverso G, Johnson C, Geng L, Favis R, Boynton K, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst. 2001; 93:858–865. PMID: 11390535.

2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001; 2:533–543. PMID: 11905707.

3. Grady WM, Markowitz SD. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet. 2002; 3:101–128. PMID: 12142355.

4. Eastwood M. Diet and intestinal disease. Compr Ther. 1977; 3:19–23. PMID: 908183.

5. Boynton KA, Summerhayes IC, Ahlquist DA, Shuber AP. DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem. 2003; 49:1058–1065. PMID: 12816901.

6. Mak T, Lalloo F, Evans DG, Hill J. Molecular stool screening for colorectal cancer. Br J Surg. 2004; 91:790–800. PMID: 15227685.

7. Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Piercall WE, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology. 2000; 119:1219–1227. PMID: 11054379.

8. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 2004; 351:2704–2714. PMID: 15616205.

9. Itzkowitz SH, Jandorf L, Brand R, Rabeneck L, Schroy PC 3rd, Sontag S, et al. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol. 2007; 5:111–117. PMID: 17161655.

10. Diehl F, Schmidt K, Durkee KH, Moore KJ, Goodman SN, Shuber AP, et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology. 2008; 135:489–498. PMID: 18602395.

11. Zou H, Taylor WR, Harrington JJ, Hussain FT, Cao X, Loprinzi CL, et al. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology. 2009; 136:459–470. PMID: 19026650.

12. Song K, Fendrick AM, Ladabaum U. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology. 2004; 126:1270–1279. PMID: 15131787.

13. Baylin SB. Mechanisms underlying epigenetically mediated gene silencing in cancer. Semin Cancer Biol. 2002; 12:331–337. PMID: 12191632.

14. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999; 21:163–167. PMID: 9988266.

15. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003; 3:253–266. PMID: 12671664.

16. Issa JP. The epigenetics of colorectal cancer. Ann N Y Acad Sci. 2000; 910:140–153. discussion 153-5. PMID: 10911911.

17. Muller HM, Oberwalder M, Fiegl H, Morandell M, Goebel G, Zitt M, et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet. 2004; 363:1283–1285. PMID: 15094274.

18. Wang DR, Tang D. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J Gastroenterol. 2008; 14:524–531. PMID: 18203283.

19. Huang Z, Li L, Wang J. Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci. 2007; 52:2287–2291. PMID: 17410438.

20. Oberwalder M, Wonter C, Wöntner C, Fiegl H, Goebel G, Zitt M, et al. SFRP2 methylation in fecal DNA--a marker for colorectal polyps. Int J Colorectal Dis. 2008; 23:15–19. PMID: 17639423.

21. Zhang W, Bauer M, Croner RS, Pelz JO, Lodygin D, Hermeking H, et al. DNA stool test for colorectal cancer: hypermethylation of the secreted frizzled-related protein-1 gene. Dis Colon Rectum. 2007; 50:1618–1626. discussion 1626-7. PMID: 17762966.

22. Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst. 2005; 97:1124–1132. PMID: 16077070.

23. Olson J, Whitney DH, Durkee K, Shuber AP. DNA stabilization is critical for maximizing performance of fecal DNA-based colorectal cancer tests. Diagn Mol Pathol. 2005; 14:183–191. PMID: 16106201.

24. Whitney D, Skoletsky J, Moore K, Boynton K, Kann L, Brand R, et al. Enhanced retrieval of DNA from human fecal samples results in improved performance of colorectal cancer screening test. J Mol Diagn. 2004; 6:386–395. PMID: 15507679.

25. Anti M, Armuzzi A, Morini S, Iascone E, Pignataro G, Coco C, et al. Severe imbalance of cell proliferation and apoptosis in the left colon and in the rectosigmoid tract in subjects with a history of large adenomas. Gut. 2001; 48:238–246. PMID: 11156647.

26. Glöckner SC, Dhir M, Yi JM, McGarvey KE, Van Neste L, Louwagie J, et al. Methylation of TFPI2 in Stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res. 2009; 69:4691–4699. PMID: 19435926.

27. Wong CM, Ng YL, Lee JM, Wong CC, Cheung OF, Chan CY, et al. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology. 2007; 45:1129–1138. PMID: 17464989.

28. Sato N, Parker AR, Fukushima N, Miyagi Y, Iacobuzio-Donahue CA, Eshleman JR, et al. Epigenetic inactivation of TPFI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene. 2005; 24:850–858. PMID: 15592528.

29. Nobeyama Y, Okochi-Takada E, Furuta J, Miyagi Y, Kikuchi K, Yamamoto A, et al. Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. Int J Cancer. 2007; 121:301–307. PMID: 17372906.

30. Rollin J, Iochmann S, Bléchet C, Hubé F, Régina S, Guyétant S, et al. Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer. Br J Cancer. 2005; 92:775–783. PMID: 15685245.

31. Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, et al. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med. 2006; 3:e486. PMID: 17194187.

32. Sova P, Feng Q, Geiss G, Wood T, Strauss R, Rudolf V, et al. Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev. 2006; 15:114–123. PMID: 16434596.